Deltex Medical Group PLC Issue of Equity (8795V)

TIDMDEMG

RNS Number : 8795V

Deltex Medical Group PLC

11 April 2023

11 April 2023

Deltex Medical Group plc

("Deltex Medical", the "Company" or the "Group")

Issue of equity to satisfy certain outstanding equity-settled non-executive directors' fees

The Board of Deltex Medical (AIM: DEMG), the global leader in oesophageal doppler monitoring, announces the issue of 9,993,805 new ordinary shares of 1p each in the capital of the Company ("Ordinary Shares"), at an issue price of 1.1 pence per new Ordinary Share (the "Issue Price"). The Issue Price represents the Company's closing mid-market price on 6 April 2023.

The new Ordinary Shares are being issued in order to satisfy certain deferred non-executive directors' fees for the year ended 31 December 2021 ("Fee Shares"). In previous years, the Company has settled the deferred non-executive directors' fees of a calendar year in July of the following year. This was last done on 16 July 2021 in respect of the fees ended 31 December 2020. The fees for the year ended 31 December 2021 were expected to be settled on or around July 2022. However, the Company was in and has continued to be in a closed period since that time. Following the publication of the results for the year ended 31 December 2022, the Company is now in a position to settle such outstanding non-executive directors' fees.

Further details of the new Ordinary Shares to be issued to each of the Deltex Medical directors are set out in the table below.

 
                                                        Resultant holding post Fee 
                                                                            Shares 
                                                  -------------------------------- 
 Director          Current Ordinary   Fee Shares       Ordinary    As a percentage 
                        Shares held       issued    Shares Held    of the enlarged 
                                                                     share capital 
 Nigel Keen              99,852,821    3,448,351    103,301,172             14.57% 
 Julian Cazalet          27,153,971    2,181,818     29,335,789              4.14% 
 Mark Wippell            11,037,875    2,181,818     13,219,693              1.86% 
 Chris Jones              4,297,291    2,181,818      6,479,109              0.91% 
 

Application for admission to trading and total voting rights

Application has been made for 9,993,805 new Ordinary Shares to be admitted to trading on AIM, which is expected to take effect on or around 17 April 2023 ("Admission").

Following Admission, the Company's issued share capital will comprise 709,057,601 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For further information, please contact:

 
 Deltex Medical Group plc                     01243 774 837 
 Nigel Keen, Chairman                          [e-mail] 
 Andy Mears, Chief Executive 
 Natalie Wettler, Group Finance Director 
 
 Nominated Adviser and Broker 
  Allenby Capital Limited                     020 3328 5656 
 Jeremy Porter / Vivek Bhardwaj (Corporate    [e-mail] 
  Finance) 
 Tony Quirke / Stefano Aquilino (Sales 
  & Corporate Broking) 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

 
 1.    Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                              PDMRs: Nigel Keen       Non-Executive Director 
                                                             - Chairman 
                                           Julian Cazalet   Non-Executive Director 
                                                           ----------------------- 
                                           Mark Wippell     Non-Executive Director 
                                                           ----------------------- 
                                           Chris Jones      Non-Executive Director 
                                                           ----------------------- 
      --------------------------------  ----------------------------------------------- 
 2.    Reason for the Notification 
      --------------------------------------------------------------------------------- 
 a)    Position/status                   See 1a) above 
      --------------------------------  ----------------------------------------------- 
 b)    Initial notification/Amendment    Initial Notification 
      --------------------------------  ----------------------------------------------- 
 3.    Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------------- 
 a)    Name                              Deltex Medical Group Plc 
      --------------------------------  ----------------------------------------------- 
 b)    LEI                               213800XN34P6LI8J6M39 
      --------------------------------  ----------------------------------------------- 
 4.    Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      --------------------------------------------------------------------------------- 
 a)    Description of                    Ordinary shares of 0.1p each in 
        the Financial                     Deltex Medical Group Plc 
        instrument, type 
        of instrument 
      --------------------------------  ----------------------------------------------- 
       Identification                    ISIN: GB0059337583 
        code 
      --------------------------------  ----------------------------------------------- 
 b)    Nature of the                     Fee shares 
        transaction 
      --------------------------------  ----------------------------------------------- 
 c)    Price(s) and volume(s)             Name              Price(s)   Volume(s) 
                                           Nigel Keen        1.1p       3,448,351 
                                                            ---------  ---------- 
                                           Julian Cazalet    1.1p       2,181,818 
                                                            ---------  ---------- 
                                           Mark Wippell      1.1p       2,181,818 
                                                            ---------  ---------- 
                                           Chris Jones       1.1p       2,181,818 
                                                            ---------  ---------- 
      --------------------------------  ----------------------------------------------- 
 d)    Aggregated information: 
      --------------------------------  ----------------------------------------------- 
 
    *    Aggregated volume               9,993,805 
 -------------------------------------  ----------------------------------------------- 
 
    *    Price                           1.1p 
 -------------------------------------  ----------------------------------------------- 
 e)    Date of the transaction           11 April 2023 
      --------------------------------  ----------------------------------------------- 
 f)    Place of the transaction          Outside a trading venue 
      --------------------------------  ----------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOESFAFMFEDSEDL

(END) Dow Jones Newswires

April 11, 2023 12:43 ET (16:43 GMT)